Hemay020 / Tianjin Hemay Pharma - LARVOL DELTA

Study Evaluating Hemay020 In Subjects With Advanced Solid Cancer (clinicaltrials.gov) - P1 | N=10 | Terminated | Sponsor: Tianjin Hemay Pharmaceutical Co., Ltd | N=55 ➔ 10 | Unknown status ➔ Terminated

Enrollment change • Metastases • Trial termination • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor